Certain Cancer Drugs May Have Fatal Side Effects Analysis
Updated: 2012-02-07 18:32:21
: Health News Certain Cancer Drugs May Have Fatal Side Effects : Analysis Print E-mail MONDAY , Feb . 6 HealthDay News Treatment with three relatively new cancer drugs may be linked to a slightly increased risk of death , a new analysis . suggests While the risk is low , it should be taken into account by doctors and patients , according to Dana-Farber Cancer Institute scientists and . colleagues The investigators analyzed the findings of 10 clinical trials that included nearly 4,700 patients treated with sorafenib Nexavar for kidney and liver cancer sunitinib Sutent for kidney cancer and gastrointestinal stromal tumor or pazopanib Votrient for kidney . cancer These so-called targeted drugs are used to stop the growth or spread of cancer by blocking the vascular endothelial growth factor

Eating more healthily and even dropping a few pounds are common resolutions, and after the over-indulgence of Christmas can initially seem very easy to stick to. But with wind, rain and even snow outside, it’s easy to understand why our … Continue reading →
It was a yet another big week for cancer-related news, and not all of it good. To save you from the task of rummaging through the papers, we’ve summarised all the important stories of the week. If you want to … Continue reading →
This week marks ten years since the Imperial Cancer Research Fund (ICRF) and the Cancer Research Campaign (CRC) merged to form Cancer Research UK. We’re now the world’s largest independent organisation dedicated to cancer research. Over the past decade, we’ve … Continue reading →
Today the National Institute of Health and Clinical Excellence – NICE, the body that decides which drugs the NHS should pay for – has given a preliminary ‘thumbs down’ to a new prostate cancer drug, abiraterone (Zytiga), after it failed … Continue reading →
A lot can happen in 7 short days, so we’ve pulled together the most interesting cancer research stories from the past week. And if the first few News Digests of 2012 are anything to go by, it looks as if … Continue reading →
Professor Gerard Evan is Head of the Department of Biochemistry at the University of Cambridge. Earlier in the week, we wrote about his work on a crucial cancer-associated gene called Myc. In this thought-provoking article, Professor Evan explains how cancer … Continue reading →
In this next post in our High-Impact Science series, we look at a rather surprising discovery made by Professor Gerard Evan and his team at the Cancer Research UK London Research Institute in the early 1990s. Their results overturned established … Continue reading →
In this month’s podcast there’s good news for UK cancer trials, as our network of Experimental Cancer Medicine Centres gets a £35 million funding boost, and we take a look at the latest research in understanding why some breast cancers … Continue reading →
It’s mid-January, and while many resolutions will still be going strong, some may have already fallen by the wayside. But it’s worth sticking to those healthy plans. Living a healthy life can make you feel more energetic and relaxed, and … Continue reading →
Amid the drama of phone hacking, economic gloom, ‘responsible’ capitalism and sinking cruise ships, the week has also seen several intriguing stories in the world of cancer research. Here’s our regular digest of the latest developments – just click on … Continue reading →